An Ebola outbreak confirmed in eastern Democratic Republic of the Congo may involve a strain that existing vaccines were not designed to stop. That is the finding that changed a serious but manageable outbreak into an emergency requiring immediate engagement from pharmaceutical companies, vaccine developers, and international financiers alongside the standard public health response infrastructure. As of May 15, 246 suspected cases and 65 deaths have been reported in Ituri province, a conflict-affected area with active gold mining, intense cross-border movement, and documented gaps in contact tracing. Suspected cases have reached Bunia, a city of 400,000. Sequencing results expected within 24 hours will determine whether existing medical countermeasures apply. Until then, the response is working against a virus it cannot yet fully name.